mercaptopurine

(redirected from 6-MP)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Wikipedia.

mercaptopurine:

see metabolitemetabolite,
organic compound that is a starting material in, an intermediate in, or an end product of metabolism. Starting materials are substances, usually small and of simple structure, absorbed by the organism as food. These include the vitamins and essential amino acids.
..... Click the link for more information.
.
References in periodicals archive ?
Allopurinol was first used to shift the metabolism of thiopurine compounds from 6-MMP to 6-TGN in poor responders to AZA or 6-MP (7).
Afterward, the patient remained on 6-MP therapy at the decreased dose of 50 mg/day, and aminotransferase levels normalized 1 month after the biopsy.
The incidence of prematurity was about 70% higher among the women treated with azathioprine or 6-MP, compared with another control group of healthy women who were not treated with the drug.
9] Nonstandard abbreviations: AZA, azathioprine; 6-MP, 6-mercaptopurine; 6-TGN, 6-thioguanine nucleotide; 6-MMP, 6-methyl mercaptopurine; TPMT, thiopurine S-methyltransferase; Ery, erythrocyte; CDAI, Crohn disease activity index; IBDQ, Inflammatory Bowel Disease Questionnaire; ITT, intention-to-treat; MCV, mean corpuscular volume.
10] Nonstandard abbreviafions: 6-MP, 6-mercaptopurine; aza, azathioprine; IBD, inflammatory bowel disease; TPMT, thiopurine S-methyltransferase; TTPA, Inosine triphosphatase; ADR, adverse drug reacfion; 6-TGN, 6-thioguanosine nucleotide; OR, odds ratio; and CI, confidence interval.
It's unnecessary to routinely monitor 6-thioguanine nucleotide (6-TGN), the active metabolite of azathioprine and 6-MP.
Erythrocyte TPMT activity was measured in EDTA blood as the conversion of 6-MP to 6-MeMP (16) and expressed as picomoles of 6-MeMP formed per hour per milligram of hemoglobin [pmol 6-MeMP * [h.
To our knowledge, this is the first LC/MS/MS method developed to quantify 6-TGNs and 6-MMPNs, the 2 major metabolites of azathioprine and 6-MP present in erythrocytes.
In February 2006, REMICADE was approved in the EU for the treatment of moderately-to- severely active UC in patients who have had an inadequate response to conventional therapy, including corticosteroids and 6-MP or AZA, or who are intolerant to or have medical contraindications for such therapies.
The influence of 6-MP and SAM concentrations on TPMT activity was assessed using eight concentrations of 6-MP (0-7.